SRPT - Sarepta Therapeutics, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $25.11 DETAILS

Stock News

Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Sarepta Therapeutics, Inc. (NasdaqGS: SRPT) (“Sarepta” or the “Company”).Sarepta is a biopharmaceutical company focused on developing treatments for rare diseases. Sarepta's most important product is Elevidys, a therapy for the treatment of Duchenne muscular dystrophy.

Aug 24, 2026 08:02 AM • businesswire.com

Bank of America Corp DE Increases Stock Position in Sarepta Therapeutics, Inc. $SRPT

Bank of America Corp DE increased its holdings in Sarepta Therapeutics, Inc. (NASDAQ: SRPT) by 26.6% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,145,926 shares of the biotechnology company's stock after buying an additional 450,336 shares during the

Aug 12, 2026 11:38 PM • defenseworld.net

Sarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook Updated

SRPT beat Q2 earnings and revenue estimates despite weaker Elevidys sales, while narrowing its 2026 product revenue outlook and tightening expense guidance.

Aug 06, 2026 11:06 AM • zacks.com

Sarepta Therapeutics Q2 Earnings Call Highlights

Sarepta Therapeutics NASDAQ: SRPT reported second-quarter 2026 total revenue of $401 million, down 34% from a year earlier, as lower ELEVIDYS sales weighed on results. The company nevertheless posted GAAP operating income of $13 million and non-GAAP operating income of $86 million, while increasing cash and investments by approximately $197 million during the quarter to $945 million.

Aug 05, 2026 09:04 PM • marketbeat.com

Sarepta Therapeutics Q2 Earnings Call Highlights

Sarepta Therapeutics (NASDAQ: SRPT) reported second-quarter 2026 total revenue of $401 million, down 34% from a year earlier, as lower ELEVIDYS sales weighed on results. The company nevertheless posted GAAP operating income of $13 million and non-GAAP operating income of $86 million, while increasing cash and investments by approximately $197 million during the quarter to $945

Aug 05, 2026 09:03 PM • defenseworld.net

Sarepta Therapeutics, Inc. (SRPT) Q2 2026 Earnings Call Transcript

Aug 05, 2026 08:30 PM • seekingalpha.com

Sarepta Therapeutics (SRPT) Q2 Earnings and Revenues Surpass Estimates

Sarepta Therapeutics (SRPT) came out with quarterly earnings of $0.64 per share, beating the Zacks Consensus Estimate of $0.58 per share. This compares to earnings of $2.02 per share a year ago.

Aug 05, 2026 05:36 PM • zacks.com

Compared to Estimates, Sarepta Therapeutics (SRPT) Q2 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Sarepta Therapeutics (SRPT) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Aug 05, 2026 05:31 PM • zacks.com

Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the second quarter of 2026. “As I begin my tenure as CEO, I am excited by the strength of Sarepta's foundation, the impact our therapies are having for patients, and the significant opportunities ahead,” said Michael Severino, MD, chief executive officer, Sarepta Therapeutics. “Our second quarter results, including $328.7 m.

Aug 05, 2026 12:05 PM • businesswire.com

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on July 28, 2026, that were previously approved by its Board of Directors under Sarepta's 2024 Employment Commencement Incentive Plan, as amended, as a material inducement to employment to Michael Severino, M.D. as Chief Executive Officer of Sarepta. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). Dr. Se.

Jul 29, 2026 01:00 PM • businesswire.com

Earnings Preview: Sarepta Therapeutics (SRPT) Q2 Earnings Expected to Decline

Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Jul 29, 2026 07:02 AM • zacks.com

Sarepta names former Abbvie president as CEO as Ingram retires

Sarepta Therapeutics said on Monday it appointed former Tessera Therapeutics CEO Michael Severino its chief executive, effective July ‌28. The longtime AbbVie executive, will succeed Doug Ingram.

Jul 27, 2026 05:19 AM • reuters.com

Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Michael Severino, M.D., as chief executive officer, effective July 28, 2026. Severino, who was previously CEO of Tessera Therapeutics, will also join Sarepta's Board of Directors. Severino succeeds Doug Ingram, who is retiring and will serve the company in an advisory capacity until the end of 2026 to ensure a smooth transiti.

Jul 27, 2026 04:30 AM • businesswire.com

SRPT Stock Slides 10% in a Week: Is Dyne Therapeutics a Threat?

Sarepta falls nearly 10% in a week after Dyne Therapeutics wins FDA priority review for a rival DMD therapy that could challenge Exondys 51 if approved.

Jul 22, 2026 06:26 AM • zacks.com

Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2026 financial results after the Nasdaq Global Market closes on Wednesday, Aug. 5, 2026. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss these results. The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentati.

Jul 22, 2026 04:30 AM • businesswire.com

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Sarepta Therapeutics, Inc. (SRPT)

SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) against certain of its officers and directors for alleged breaches of fiduciary duty.

Jul 13, 2026 05:46 AM • globenewswire.com (Hide legal announcements)

2 Beaten-Down Stocks That Still Aren't Worth Buying

Recursion Pharmaceuticals has yet to prove that its approach to developing medicines is superior. Sarepta Therapeutics will struggle to shake off safety concerns about its most important therapy.

Jul 11, 2026 12:30 PM • fool.com

Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout

Biotech is the story at midday Friday, and it's not a pretty one for shareholders who chased the sector's monster 2026 run.

Jul 10, 2026 08:04 AM • 247wallst.com

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on June 30, 2026 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta's 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 30 individuals hired by Sarepta in the second quarter of 2026. The equity awards were approved in accordance with Nasdaq Listing Rule.

Jun 30, 2026 12:25 PM • businesswire.com

Sarepta Moves Closer To FDA Approval For Duchenne Muscular Dystrophy Drugs

The U.S. Food and Drug Administration (FDA) accepted on Tuesday Sarepta Therapeutics Inc.'s (NASDAQ:SRPT) supplemental New Drug Applications seeking to convert the accelerated approvals of AMONDYS 45 (casimersen) and VYONDYS 53 (golodirsen) into traditional approvals for Duchenne muscular dystrophy (DMD).

Jun 30, 2026 08:44 AM • benzinga.com